Actively Recruiting
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Led by Samsung Medical Center · Updated on 2025-05-21
600
Participants Needed
1
Research Sites
512 weeks
Total Duration
On this page
Sponsors
S
Samsung Medical Center
Lead Sponsor
S
Samsung Genomic Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
CONDITIONS
Official Title
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically diagnosed Hodgkin or non-Hodgkin lymphoma
- Age 20 years or older
- Require systemic chemotherapy with curative intent
- Provide written informed consent
You will not qualify if you...
- Diagnosis of myeloid malignancy
- Diagnosis of multiple myeloma
- Do not require systemic chemotherapy with curative intent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, South Korea, 135-710
Actively Recruiting
Research Team
S
Seok Jin Kim, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here